ABEO

Abeona TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

Current thesis

Composite grade B from latest DB weights. Momentum 81.2 / Value 44.2

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +26.0.

What can break

Mixed signals. Wait for cleaner trend confirmation.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

0 · Net Neutral

AI TargetsBase - · Bull - · Bear -

Data freshness

Prices

As of 2026-07-20

Fundamentals

As of 2026-07-20 • Vendor: Data Vendor v1

Scores

As of 2026-07-20 • Model: HYBRID_IC_RP

AI Memo

Unavailable: No memo yet

Investment thesis

As of 2026-07-20

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net Neutral

Target $19.71

Why

Momentum81 · Δ7d +26.0

Value44 · Δ7d 0.0

SentimentN/A · Δ7d -

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Momentum · See technicals

Momentum

40% active weight

Current posture

7d trendImproving

Δ7d

+26.0

Δ21d

+35.4

Value

60% active weight

Current posture

7d trendFlat

Δ7d

0.0

Δ21d

-0.1

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade B. Momentum 81.2 / Value 44.2

Fundamentals (TTM)

As of 2026-07-20

Market Cap

$369.33M

Beta

1.17

Shares Out

57M

P/E (TTM)

4.7

P/S (TTM)

707.20

P/FCF (TTM) · Derived

-4.39

Rev YoY

-100.0%

EPS YoY

+24.8%

Gross Margin

+34.6%

Op Margin

+17289.3%

Net Debt

-$166.44M

Current Ratio

5.89

As of 2026-07-20 • Updated nightlySource: Internal modelMethodology